Economic Outcomes of Medicare Reimbursement Policy Change on Erythropoiesis-Stimulating Agents in Cancer Patients
نویسندگان
چکیده
منابع مشابه
An economic evaluation of erythropoiesis-stimulating agents in CKD.
BACKGROUND The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (> 12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs. STUDY DESIGN Cost-utility analysis. SETTING & PARTICIPANTS Publicly...
متن کاملSafety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
BACKGROUND New data on erythropoiesis-stimulating agents (ESAs) regarding overall survival and disease progression-related outcomes in patients with breast cancer receiving chemotherapy are presented in a meta-analysis of controlled trials of ESA use (epoetin α, epoetin β, darbepoetin α, biosimilars). PATIENTS AND METHODS A literature search identified reports from January 1997 through March ...
متن کاملAn economic evaluation of erythropoiesis-stimulating agents in CKD
CRD summary The study assessed the cost-effectiveness of treating non-dialysis and dialysis patients with chronic kidney disease with erythropoiesis-stimulating agents (ESAs) to a low, intermediate or high haemoglobin level target. The authors concluded that targeting ESA treatment to high haemoglobin levels was not associated with overall clinical benefit and resulted in considerable additiona...
متن کاملEnrollment of older persons in cancer trials after the medicare reimbursement policy change.
BACKGROUND The Medicare program was revised in 2000 to authorize payment of routine care costs for patients in clinical trials. This study evaluates the impact of the Medicare reimbursement policy change on enrollment of older patients into cancer trials. METHODS We conducted a longitudinal analysis of the enrollment of older patients in National Cancer Institute-sponsored lung, colorectal, b...
متن کاملShould erythropoiesis-stimulating agents be used in predialysis patients?
Anemia results from insufficient production of erythropoietin by the kidneys and is a common complication of chronic kidney disease. It is present in most patients with stage 4 and 5 chronic kidney disease. Studies have linked untreated anemia in chronic kidney disease to worsening cardiovascular complications, possible acceleration to end-stage renal disease, and death. Administration of eryth...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2018
ISSN: 1098-3015
DOI: 10.1016/j.jval.2018.04.151